


Bogin symposium 2017 Wat brengt ons de implementatie van de FMD?












3M Belance Applied to Life.	Æ		Apobiologix	APOTEX	BioPharma
Bodringer ingelbeim	CHEMO	cinfa	Cipla	<u>()</u>	(teans
FARMOZ	Stormycon	Wi san	GLARY REPERTAN		jgl 📀
I 💽 KRKA.		S medichem		NUBROK	[]]Mylan
Considering Street	🤪 polpharma	SAMSUNG HOLPHS		(5) sopharma	STADA
Synthesis	17370	ZONTIVA	🍲 acino	Anapharm	👌 Bilev Pharmages
BILLEY PHARMA EAST	DISPHAR	Formaprojects	Glenmark	HETERO	Фармар

3

aese	apogen	• 9 ,0200253972		BOGIN
FeBe(Gon	GERME	IEIS	igL ment	Q-AWW
C medicines	progenerika	Traducenci Lebov PL	8	Z martin
CAFF	CEA	Rinnakkatslääkkont	FGI. 💶 777777W	e
GENAS-	Intergenerika	Coverskeverdand		





Why? What?

Falsified Medicines Directive

- EU directives set out results that all EU Member States must achieve (>< Regulation)
- FMD (2011/62/EU): the prevention of the entry into the legal supply chain of falsified medicinal products


Delegated Regulation

• A DR allows Parliament and the Council to delegate to the Commission the power to adopt "non-legislative acts of general application to supplement or amend certain non-essential elements of a legislative act"


patients • quality • value • sustainability • partnership



*Delegated Regulation, Art 25 (1)




patients • quality • value • sustainability • partnership







When?


- 8 June 2011: Adoption FMD
- 2 October 2015: Adoption DR by EC
- 9 February 2016: Publication DR in the Official Journal
- Transitional measures
 - 3 year transition phase (till 9 February 2019)
 - Fade-out phase till expiry date of products
 - 6 additional years for Belgium, Italy and Greece




C medicines	Estimated costs
Average company	 Update packaging and production lines: € 5 million Annual running and maintenance costs: € +2 million
Total pharma industry	 Update packaging and production lines: € 5 billion EMVS: implementation cost: € +90 Mio annual running cost: € +90 Mio
	Implementation cost: details from technical workshop at EGA on 22 February 2012











EMVO Observations

- Program Progress
 - 26 NMVOs (>75%) founded, 15 contracts signed
 - 22 Countries have chosen their Provider but the contract takes more time than expected
 - Countries choose Blueprint, a few (technical) assessments still ongoing
- To be improved
 - Approx. 50% of Countries are still behind Schedule
 - Stakeholder alignment in MOU and Statutes not complete in a few Countries (e.g.

Pharmacies or Wholesalers not integrated in NMVO set up)





Safer medicines = less medicines?

• Financial burden industry

- → Estimated € 5 billion for adoption of production/packaging lines
- → Implementation cost of EMVS: estimated € 90 million
- → Annual running cost of EMVS: estimated € 90 million
- Regulatory Impact Variations
 Workload for industry and NCAs bottle necks?
- Reduced availability → decreased access... or not?
 - ightarrow Voluntary use of SF
 - → Multi market coding (Pack coding guideline)
 - \rightarrow Loss of profitability? \rightarrow withdrawal of products?

25-11-2017



Thank you

